Jump to main content
Jump to site search

Issue 53, 2019
Previous Article Next Article

A 224Ra-labeled polyoxopalladate as a putative radiopharmaceutical

Author affiliations

Abstract

Despite their attractive properties, internal targeted alpha therapies using 223/224Ra are limited to bone-seeking applications. As there is no suitable chelator available, the search for new carriers to stably bind Ra2+ and to connect it to biological target molecules is necessary. Polyoxopalladates represent a class of compounds where Ra2+ can be easily introduced into the Pd-POM core during a facile one-pot preparation. Due to the formation of a protein corona, the connection to other targeting (bio)macromolecules is possible.

Graphical abstract: A 224Ra-labeled polyoxopalladate as a putative radiopharmaceutical

Back to tab navigation

Supplementary files

Article information


Submitted
03 Apr 2019
Accepted
04 Jun 2019
First published
04 Jun 2019

Chem. Commun., 2019,55, 7631-7634
Article type
Communication

A 224Ra-labeled polyoxopalladate as a putative radiopharmaceutical

M. Gott, P. Yang, U. Kortz, H. Stephan, H. Pietzsch and C. Mamat, Chem. Commun., 2019, 55, 7631
DOI: 10.1039/C9CC02587A

Social activity

Search articles by author

Spotlight

Advertisements